SG11201607109QA - Antibodies that bind egfr and erbb3 - Google Patents

Antibodies that bind egfr and erbb3

Info

Publication number
SG11201607109QA
SG11201607109QA SG11201607109QA SG11201607109QA SG11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA
Authority
SG
Singapore
Prior art keywords
erbb3
antibodies
bind egfr
egfr
bind
Prior art date
Application number
SG11201607109QA
Other languages
English (en)
Inventor
Ton Logtenberg
Mark Throsby
Robertus Cornelis Roovers
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11201607109QA publication Critical patent/SG11201607109QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201607109QA 2014-02-28 2015-02-27 Antibodies that bind egfr and erbb3 SG11201607109QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14157351 2014-02-28
PCT/NL2015/050124 WO2015130172A1 (fr) 2014-02-28 2015-02-27 Anticorps qui se lient à l'egfr et à l'erbb3

Publications (1)

Publication Number Publication Date
SG11201607109QA true SG11201607109QA (en) 2016-09-29

Family

ID=50184826

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607109QA SG11201607109QA (en) 2014-02-28 2015-02-27 Antibodies that bind egfr and erbb3

Country Status (9)

Country Link
US (3) US10844127B2 (fr)
EP (2) EP3786186A1 (fr)
JP (1) JP6771385B2 (fr)
AU (1) AU2015223566B2 (fr)
CA (1) CA2941030A1 (fr)
ES (1) ES2816624T3 (fr)
NZ (1) NZ724013A (fr)
SG (1) SG11201607109QA (fr)
WO (1) WO2015130172A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506235B (zh) 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
IL301147A (en) * 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
ES2693596T3 (es) 2015-07-10 2018-12-12 Merus N.V. Anticuerpo que se une a CD3 humano
EP3912998A3 (fr) * 2015-10-23 2022-02-23 Merus N.V. Molécules de liaison qui inhibent la croissance d'un cancer
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
US20180362654A1 (en) 2015-12-11 2018-12-20 Regeneron Pharmaceuticals, Inc. Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade
US11124575B2 (en) * 2017-02-22 2021-09-21 University Of Saskatchewan EGFR-binding agents and uses thereof
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
WO2019031965A1 (fr) * 2017-08-09 2019-02-14 Merus N.V. Anticorps qui se lient à l'egfr et à cmet
TW202003569A (zh) 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體
CA3124688A1 (fr) 2018-12-31 2020-07-09 Merus N.V. Multimeres multivalents tronques
BR112021016094A2 (pt) 2019-02-14 2021-10-26 Merus N.V. Combinações de porções de ligação que se ligam ao egfr, her2 e her3
MX2021013646A (es) 2019-05-09 2022-01-31 Merus Nv Dominios variantes para las proteínas multimerizantes y su separación.
BR112022003143A2 (pt) 2019-08-19 2022-05-17 Merus Nv Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.
WO2021215926A1 (fr) 2020-04-24 2021-10-28 Merus N.V. Traitement de cancers avec un anticorps se liant à lgr5 et egfr
CN116710472A (zh) 2020-12-15 2023-09-05 美勒斯公司 利用结合lgr5和egfr的抗体治疗癌症
CN118055949A (zh) 2021-10-06 2024-05-17 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
WO2023172134A1 (fr) 2022-03-07 2023-09-14 Merus N.V. Traitement avec un anticorps qui se lie à egfr et à cmet.
TW202337909A (zh) 2022-03-07 2023-10-01 荷蘭商美勒斯公司 包括結合EGFR及cMET之抗體的組合療法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2199216T3 (es) 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP1533380B1 (fr) 1999-04-15 2009-11-04 Crucell Holland B.V. Production de protéine de recombinaison dans une cellule humaine comprenant au moins une protéine E1 d'adénovirus
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ATE467682T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2004061104A2 (fr) 2003-01-07 2004-07-22 Symphogen A/S Methode de production de proteines polyclonales de recombinaison
WO2005000894A2 (fr) 2003-06-25 2005-01-06 Crucell Holland B.V. Molecules de liaison pour traiter les malignites de cellules myeloides
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
US7858086B2 (en) 2004-10-12 2010-12-28 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007135216A (ru) 2005-02-23 2009-03-27 Мерримак Фармасьютикалз, Инк. (Us) Биспецифические связывающие агенты для модулирования биологической активности
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1999154B1 (fr) 2006-03-24 2012-10-24 Merck Patent GmbH Domaines de proteine heterodimerique d'ingenierie
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
DK2129396T3 (da) * 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
CA2682626A1 (fr) 2007-04-03 2008-10-09 Micromet Ag Elements de liaison bispecifiques specifiques d'especes croisees
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
CA2691378A1 (fr) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Anticorps contre la r-spondine humaine et utilisation associee en vue de l'inhibition du signalement de beta-catenine et traitement du cancer
EP2211903A4 (fr) 2007-10-17 2011-07-06 Nuvelo Inc Anticorps anti-cll-1
CA2711843C (fr) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Procedes de diagnostic du her-2
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
JP5530367B2 (ja) 2008-02-05 2014-06-25 ザイムワークス，インコーポレイテッド 分子動力学を使用してタンパク質またはその他のバイオポリマー中の相関残基を決定するための方法
CA2729095C (fr) 2008-06-27 2018-12-04 Merus B.V. Methode de production d'un mammifere murin transgenique
KR101706255B1 (ko) 2008-08-29 2017-02-14 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
KR20110120891A (ko) 2009-01-15 2011-11-04 래버러토리 코포레이션 오브 아메리카 홀딩스 Ｈｅｒ-３의 측정에 의한 환자 반응의 결정 방법
SG172977A1 (en) 2009-01-26 2011-08-29 Genmab As Methods for producing mixtures of antibodies
EP2408817B1 (fr) * 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Anticorps anti-her di-spécifiques
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
EA201200195A1 (ru) * 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011056124A1 (fr) 2009-11-04 2011-05-12 Affibody Ab Polypeptides de liaison de her3
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HUE029785T2 (en) 2010-02-08 2017-04-28 Regeneron Pharma Common mouse light chain
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
UA114883C2 (uk) 2010-08-20 2017-08-28 Новартіс Аг Антитіло до рецептора епідермального фактора росту-3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US20140056898A1 (en) 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CA2828043A1 (fr) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Vaincre la resistance a des inhibiteurs de la voie erbb
EP2688909A2 (fr) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Immunoglobulines hétéro-dimériques
ES2657862T3 (es) 2011-05-13 2018-03-07 Gamamabs Pharma Anticuerpos contra HER3
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
KR20140069331A (ko) 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ＥｒｂＢ3 항체 및 이의 용도
EP3608340A1 (fr) 2011-11-23 2020-02-12 Medlmmune, LLC Molécules de liaison propres à her3 et utilisation de celles-ci
EP2788381A2 (fr) 2011-12-05 2014-10-15 Novartis AG Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine iii et le domaine iv d'her3
UY34487A (es) 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
JP6231503B2 (ja) 2012-03-09 2017-11-15 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｐＨセンサー
CA2865082A1 (fr) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
CA2883264A1 (fr) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Ligands her2 bispecifiques pour la therapie du cancer
CN113201073A (zh) 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
AU2014240457A1 (en) 2013-03-14 2015-08-13 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2981828A1 (fr) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systèmes et procédés pour faciliter le diagnostic, le pronostic et le traitement d'un cancer sur la base de la détection de l'activation de her3
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
ES2693596T3 (es) 2015-07-10 2018-12-12 Merus N.V. Anticuerpo que se une a CD3 humano
EP3912998A3 (fr) 2015-10-23 2022-02-23 Merus N.V. Molécules de liaison qui inhibent la croissance d'un cancer
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
CA3058341A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps pour le traitement de tumeurs positives erbb-2/erbb-3

Also Published As

Publication number Publication date
EP3786186A1 (fr) 2021-03-03
JP2017512756A (ja) 2017-05-25
WO2015130172A1 (fr) 2015-09-03
NZ724013A (en) 2019-11-29
US11820825B2 (en) 2023-11-21
US20240052043A1 (en) 2024-02-15
AU2015223566A1 (en) 2016-09-01
US20170058035A1 (en) 2017-03-02
ES2816624T3 (es) 2021-04-05
AU2015223566B2 (en) 2020-10-08
US20210155698A1 (en) 2021-05-27
CA2941030A1 (fr) 2015-09-03
US10844127B2 (en) 2020-11-24
JP6771385B2 (ja) 2020-10-21
EP3110846B1 (fr) 2020-08-19
EP3110846A1 (fr) 2017-01-04

Similar Documents

Publication Publication Date Title
ZA202105920B (en) Antibody that binds erbb-2 and erbb-3
SG11201607109QA (en) Antibodies that bind egfr and erbb3
HK1255067A1 (zh) 抗c10orf54抗體及其用途
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
IL252929A0 (en) Anti-acth antibodies from humans and their use
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
IL247590A0 (en) Bispecific antibodies and their uses
HK1245811A1 (zh) 結合人c6的抗體及其用途
PT3110849T (pt) Anticorpo que liga erbb-2 e erbb-3